{"url":"https://lda.senate.gov/api/v1/filings/86926772-dfd5-45d7-97ab-bbbfd5014ed0/","filing_uuid":"86926772-dfd5-45d7-97ab-bbbfd5014ed0","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2021,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/86926772-dfd5-45d7-97ab-bbbfd5014ed0/print/","filing_document_content_type":"text/html","income":null,"expenses":"277000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Grant Erdel","dt_posted":"2021-10-20T13:28:05.007000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 Corporate Drive","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Mahwah","registrant_state":"NJ","registrant_zip":"07430","registrant":{"id":401104388,"url":"https://lda.senate.gov/api/v1/registrants/401104388/","house_registrant_id":43579,"name":"GLENMARK PHARMACEUTICALS USA","description":"Pharmaceutical manufacturing","address_1":"750 Corporate Drive","address_2":null,"address_3":null,"address_4":null,"city":"Mahwah","state":"NJ","state_display":"New Jersey","zip":"07430","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLINE SUN","contact_telephone":"+1 201-331-4522","dt_updated":"2026-03-28T17:14:48.038820-04:00"},"client":{"id":201662,"url":"https://lda.senate.gov/api/v1/clients/201662/","client_id":12,"name":"GLENMARK PHARMACEUTICALS USA","general_description":"Pharmaceutical manufacturing","client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-03-21"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicaid generics penalty","foreign_entity_issues":"Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":65608,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"ERDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.","foreign_entity_issues":"Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":65608,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"ERDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}